Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8206560 | 0.84 | GAA (0.50) | CA2CA7CA9BCHEACHE | |
| SCHEMBL8322191 | 0.84 | GAA (0.50) | CA2CA7CA9BCHEACHE | |
| SCHEMBL8187178 | 0.84 | GAA (0.50) | CA2CA7CA9BCHEACHE | |
| SCHEMBL6934702 | 0.82 | GAA (0.48) | CA2CA7CA9BCHEACHE | |
| SCHEMBL1904849 | 0.82 | CA2 (0.47) | CA2CA7CA9BCHEACHE | |
| SCHEMBL11784096 | 0.82 | BCHE (0.49) | CA2CA7CA9BCHEACHE | |
| SCHEMBL7259363 | 0.81 | CA2 (0.46) | CA2CA7CA9BCHEACHE | |
| SCHEMBL7341952 | 0.79 | PPARG (0.57) | CA2CA7GAALMNAPPARG | |
| SCHEMBL17023782 | 0.79 | CYP24A1 (0.48) | CA2CA7CA9BCHEACHE | |
| SCHEMBL25224824 | 0.78 | CA2 (0.44) | CA2CA7CA9BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | CA2 3519/4885CA7 1521/4885CA9 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.